EP2534135A2 - Nouvelles formes de chlorhydrate d'ivabradine - Google Patents

Nouvelles formes de chlorhydrate d'ivabradine

Info

Publication number
EP2534135A2
EP2534135A2 EP11702672A EP11702672A EP2534135A2 EP 2534135 A2 EP2534135 A2 EP 2534135A2 EP 11702672 A EP11702672 A EP 11702672A EP 11702672 A EP11702672 A EP 11702672A EP 2534135 A2 EP2534135 A2 EP 2534135A2
Authority
EP
European Patent Office
Prior art keywords
ivabradine hydrochloride
ivabradine
preparation
amorphous
isopropanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11702672A
Other languages
German (de)
English (en)
Inventor
Berta Kotar-Jordan
Urska Gojak
Matej Smrkolj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRKA dd filed Critical KRKA dd
Priority to EP15151073.2A priority Critical patent/EP2902384B1/fr
Priority to PL15151073T priority patent/PL2902384T3/pl
Publication of EP2534135A2 publication Critical patent/EP2534135A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to novel crystalline forms of ivabradine hydrochloride and pharmaceutical compositions prepared therefrom.
  • Ivabradine and addition salts thereof with a pharmaceutically acceptable acid have very valuable pharmacological and therapeutic properties, especially bradycardic properties, making those compounds useful in the treatment or prevention of various clinical situations of myocardial ischemia such as angina pectoris, myocardial infarct and associated rhythm disturbances, and also in various pathologies involving rhythm disturbances, especially supraventricular rhythm disturbances, and in heart failure.
  • ivabradine hydrochloride The preparation and therapeutic use of ivabradine hydrochloride have been described in EP534859. Novel crystalline forms of ivabradine hydrochloride have been described in EP1589005, EP1695710, EP1695709, EP1707562, EP1695965, EP1775288 and EP1775287. Improved processes for preparation of ivabradine are disclosed in EP1589005, EP1589014, EP1614687, EP1598333, O2008065681.
  • Figure 1 is an X-ray powder diffraction pattern of ivabradine hydrochloride form Z .
  • Figure 2 is an X-ray powder diffraction pattern of ivabradine hydrochloride form X.
  • Figure 3 is an X-ray powder diffraction pattern of ivabradine hydrochloride form K.
  • Figure 4 is a HPLC chromatogram of ivabradine in tablets prepared according to example 23 after being held at 50°C/75% RH for 1 month.
  • the X-ray powder diffraction pattern was obtained by Philips P 3040/60 X' Pert powder diffractometer, X' celerator detector at CuK radiation, 1.54178 A, 3° ⁇ 2 ⁇ 30°.
  • HPLC chromatogram of related substances of ivabradine was obtained on a high performance liquid chromatograph with UV detector. Chromatographic separation was achieved using Atlantis dC18 150x4.6 mm, 3 ⁇ analytical column. Chromatographic conditions used were: sample concentration of 1.5 mg/ml, detection at 286 nm, flow of 1.0 ml/min, volume of injection 5 ⁇ . A gradient elution using mobile phase A (0.01M CH 3 COONH 4 pH 7.5) and mobile phase B (CH 3 CN) was employed with time table (Omin 20%B, lOmin 20%B, 25min 30%B, 30min 30%B, 40min 70%B, 45min 85%B, 60min 85%B, 60.5min 20%B,65min 20%B, ) .
  • a novel crystalline form of a drug substance may display different melting point, hygroscopicity, stability, solubility and/or dissolution rate, crystallinity, crystal habits, bioavailability and formulation handling characteristics, which are among the numerous properties that need to be considered in preparing a medicament that can be effectively administered.
  • a novel crystalline form of ivabradine hydrochloride according to the present invention designated as form Z is characterized by an X-ray powder diffraction pattern having peaks at about 3.9, 15.1, 16.2, 16.6 and 17.8 ⁇ 0.2 degrees two-theta.
  • Ivabradine hydrochloride form Z can be further characterized by X-ray powder diffraction peaks at about 3.9, 15.1, 16.2, 16.6, 17.8, 19.0, 22.0 and 24.7 ⁇ 0.2 degrees two-theta.
  • the X- ray powder diffraction pattern of ivabradine hydrochloride form Z is shown in Figure 1.
  • Isopropanol which is brought into contact with the amorphous ivabradine hydrochloride can have a temperature of 15-30 °C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C.
  • the temperature of the mixture of isopropanol and amorphous ivabradine hydrochloride during the dissolving step can be a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C.
  • the temperature of the obtained solution subjected to stirring during stirring step b) can be a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C.
  • the reaction mixture comprising the precipitate can have a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C until the begin of and/or during the recovery of said precipitate.
  • isopropanol used for dissolving compounds such as for dissolving amorphous ivabradine hydrochloride, ivabradine and/or hydrochloric acid can generally be isopropanol of any degree of purity.
  • isopropanol used for dissolving compounds can be pure or essentially pure isopropanol.
  • isopropanol used for dissolving compounds can be a fluid consisting of or comprising the chemical compound isopropanol in an amount of at least 92 wt.-%, preferably in an amount of at least 97 wt.-%, more preferably in an amount of at least 99 wt.-%, each based on the total weight of said fluid consisting of or comprising isopropanol.
  • Isopropanol which is brought into contact with ivabradine can have a temperature of 15-30 °C, preferably a temperature of 20- 25°C, more preferably a temperature of 21-23°C.
  • Ivabradine dissolved in isopropanol can have a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C, before and/or during the step of adding hydrochloric acid in isopropanol to ivabradine dissolved in isopropanol.
  • Both hydrochloric acid in isopropanol and ivabradine dissolved in isopropanol can have a temperature of 15-30 °C, preferably a temperature of 20-25°C, more preferably a temperature of 21- 23°C, before and/or during the step of adding hydrochloric acid in isopropanol to ivabradine dissolved in isopropanol.
  • the obtained solution subjected to stirring can have a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21- 23°C.
  • the reaction mixture comprising the precipitate can have a temperature of 15-30°C, preferably a temperature of 20-25°C, more preferably a temperature of 21-23°C before the begin of and/or during the recovery of said precipitate.
  • the mixture hydrochloric acid in isopropanol may optionally comprise water or can be free or essentially free of water.
  • a mixture comprising hydrochloric acid, isopropanol and water may comprise HCl in an amount of at least 1 wt.-%, preferably of at least 10 wt.-%, more preferably of at least 15 wt.-%, in particular from about 20 to 38 wt.-% HCl, based on the total weight of HCl and water.
  • the temperature of crystallization of ivabradine hydrochloride crystalline form Z is between 20 and 25°C, and/or the ratio of isopropanol to ivabradine hydrochloride during crystallization is preferably between 4.5 and 5.5 ml/g.
  • ivabradine hydrochloride form Z gives ivabradine hydrochloride of a very good purity such as a purity level of more than 99.0 %, preferably 99.5 %, and most preferably 99.9 % (HPLC) .
  • a novel crystalline form of ivabradine hydrochloride according to present invention designated as form X is characterized by an X-ray powder diffraction pattern having peaks at about 11.0, 16.5, 16.9, 21.8 and 22.4 ⁇ 0.2 degrees two-theta.
  • Ivabradine hydrochloride form X can be further characterized by X-ray powder diffraction peaks at about 11.0, 16.5, 16.9, 21.8, 22.4, 23.7, 26.0 and 27.9 ⁇ 0.2 degrees two-theta.
  • the X- ray powder diffraction pattern of ivabradine hydrochloride form X is shown in Figure 2.
  • a process for preparation of ivabradine hydrochloride form X according to present invention can be characterized in that it comprises the step of drying ivabradine hydrochloride form Z for at least 2 hours at 20-30°C.
  • a novel crystalline form of ivabradine hydrochloride according to present invention designated as form K is characterized by an X-ray powder diffraction pattern having peaks at about 8.6, 14.6, 17.2, 18.3 and 21.6 ⁇ 0.2 degrees two-theta.
  • Ivabradine hydrochloride form K can be further characterized by X-ray powder diffraction peaks at about 8.6, 14.6, 17.2, 18.3, 21.6, 22.3, 24.0 and 26.4 ⁇ 0.2 degrees two-theta.
  • the X-ray powder diffraction pattern of ivabradine hydrochloride form K is shown in Figure 3.
  • a process for preparation of ivabradine hydrochloride form K according to present invention can be characterized in that it comprises the step of drying ivabradine hydrochloride form Z or form X for at least 2 hours at 50-80°C, preferably at 60- 75°C, more preferably at 65-72°C.
  • the average particle size of ivabradine hydrochloride forms Z, X and K according to the present invention can be in the range of 0.1-600 ⁇ , preferably 10-200 ⁇ , most preferably 10-100 ⁇ determined by laser diffraction using a Malvern Mastersizer 2000 laser diffraction instrument.
  • the samples for analysis may be prepared in particular as set forth in the Example section .
  • the obtained ivabradine hydrochloride can be sieved, milled or micronized optionally together with other excipients. In the case of agglomerates, ultrasonication can be used.
  • Optical purity of ivabradine hydrochloride used in the present invention can be more than 99.0%, preferably more than 99.5%, most preferably more than 99.9% (chiral HPLC) .
  • Ivabradine base used in the present invention can be prepared according to methods disclosed in EP534859, WO2005110993, WO2005111026, WO2005111027 , WO2005123659, WO2008065681, WO2008125006, WO2008146308, WO2009062377 , CN101544605, CN101343249, WO2009153461, EP2145871 and/or PCT/EP2009/009234.
  • the present invention also relates to pharmaceutical compositions comprising ivabradine hydrochloride, wherein ivabradine hydrochloride forms Z, X and/or K are used in the process of preparation of such compositions.
  • the present invention relates to pharmaceutical compositions comprising amorphous ivabradine hydrochloride.
  • Active substances in an amorphous form can be better soluble and dissolve more rapidly than active substances in a crystalline form.
  • amorphous substances lack physical stability. They tend to crystallize and are hygroscopic.
  • amorphous ivabradine can be formulated into a stable pharmaceutical composition with improved solubility properties and improved bioavailability characteristics.
  • Amorphous ivabradine hydrochloride can be prepared by precipitation, in particular can be prepared by precipitation alone or on a pharmaceutically acceptable carrier.
  • amorphous ivabradine is prepared by spray drying the solution or dispersion comprising ivabradine hydrochloride and optionally one or more pharmaceutically acceptable carrier (s).
  • amorphous ivabradine according to present invention can be prepared by spraying the solution or dispersion of ivabradine hydrochloride on a solid carrier.
  • crystalline forms Z, X and K are used in the preparation of amorphous ivabradine hydrochloride, however, other crystalline forms of ivabradine hydrochloride, already know in prior art, can also be used, such as crystalline forms ⁇ , ⁇ , d , Y, yd, ⁇ and 5d.
  • pharmaceutically carrier means any pharmaceutically acceptable excipient.
  • carriers are selected from a group of stabilizers described below.
  • the present invention provides a process for the preparation of amorphous ivabradine hydrochloride, which process comprises :
  • ivabradine hydrochloride comprising or consisting of ivabradine hydrochloride selected from the group consisting of ivabradine hydrochloride crystalline forms Z, X, K, ⁇ , ⁇ , ⁇ , ⁇ , yd, ⁇ , 5d, and mixtures thereof, preferably selected from the group consisting of ivabradine hydrochloride crystalline forms Z, X, K, and mixtures thereof,
  • step b) preparing amorphous ivabradine hydrochloride from said ivabradine hydrochloride provided in step a) .
  • the present invention also provides a pharmaceutical composition comprising amorphous ivabradine hydrochloride obtained and/or obtainable according to procedures taught in the present invention.
  • the pharmaceutical composition comprising amorphous ivabradine hydrochloride in particular in the form of a tablet, can comprise at least one further ingredient, preferably at least two further ingredients, more preferably at least three further ingredients, in particular four ingredients selected from the group consisting of microcrystalline cellulose, maize starch, magnesium stearate, and colloidal silicon dioxide (in particular colloidal silicon dioxide, anhydrous).
  • Stabilizers can be added in granulating liquid in order to stabilize dissolved active ingredient, to increase the solubility of the drug and/or to inhibit the recrystallisation of the drug.
  • stabilizers can be included directly to the tabletting mixture.
  • the term "granulating liquid" according to the present invention can refer to water, alcohol, water/alcohol mixture, or an aqueous, alcoholic or aqueous/alcoholic solution, dispersion or suspension, which contains purified water or demineralised water or lower alcohols such as methanol, ethanol, isopropanol or mixtures thereof as diluents and the substance which is dispersed, suspended or dissolved in the diluent.
  • the said substance can have known functions of excipients used in the solid pharmaceutical composition according to the invention such as binder, surfactant, stabilizing agent or crystallization inhibitor.
  • solvents used in the preparation of amorphous ivabradine hydrochloride preferably the solvents are water and/or alcohols such as ethanol, methanol and/or isopropanol .
  • coprecipitate refers to compositions comprising amorphous ivabradine together with at least one pharmaceutically acceptable carrier, being prepared by removing solvent from a solution comprising both of them.
  • Pharmaceutical excipient(s) can be selected from the group consisting of fillers, diluents, binders, lubricants, disintegrants , glidants, stabilizers and film-forming agents.
  • One or more different fillers/diluents can be used, such as lactose (anhydrous, monohydrate, spray dried lactose etc.), microcrystalline cellulose, powdered cellulose, silicified microcrystalline cellulose, starches, pregelatinized starch, mannitol, sorbitol, lactitol, xylitol, calcium phosphate, calcium hydrogen phosphate, calcium carbonate, magnesium carbonate, sucrose, glucose, fructose, dextrates, maltodextrins , calcium lactate or combined diluents, such as Cellactose (spray-dryed lactose and powdered cellulose) and Starlac (co-dryed lactose and starch) .
  • lactose anhydrous, monohydrate, spray dried lactose etc.
  • microcrystalline cellulose powdered cellulose
  • silicified microcrystalline cellulose starches
  • pregelatinized starch mannitol
  • One or more binders can be selected from maltodextrin, povidone or polyvinylpyrrolidone, copovidone (Plasdone S-630), microcrystalline cellulose, hydroxypropylcellulose, low- substituted hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose and/or other cellulose ethers, dextrates, polyethylene glycol, starch, pregelatinized starch, gelatine, polymethacrylates .
  • one or more disintegrants and/or superdisintegrants can also be included into a pharmaceutical composition, such as starch(es) (e.g. maize starch, potato starch), modified starch (es) (e.g. sodium starch glycolate) , modified cellulose (e.g. croscarmellose, i.e. cross-linked carboxymethlycellulose sodium) , cross-linked polyvinylpyrrolidone (crospovidone) , low-substituted hydroxypropylcellulose, microcrystalline cellulose, carboxymethylcellulose sodium, carboxymethylstarch sodium, Amberlite ® , alginic acid, sodium alginate, guar gum, gellan gum, xantan gum and/or calcium silicate.
  • starch(es) e.g. maize starch, potato starch
  • modified starch e.g. sodium starch glycolate
  • modified cellulose e.g. croscarmellose, i.e. cross-linked carboxymeth
  • stabilizers which improve the physical and chemical stability of amorphous ivabradine hydrochloride, can be used in a pharmaceutical composition of the present invention.
  • Such stabilizers can be (but are not limited to) polyvinylpyrrolidone and derivatives thereof, maltodextrin, cyclodextrins (hydroxypropyl- ⁇ -cyclodextrin) , xanthan gum, pectins, alginates, tragacanth, arabic gum, carrageenans , agar, hydroxypropylcellulose, bentonite, magnesium aluminium silicate, sodium hydroxide, meglumine, sodium hydrogen carbonate, calcium carbonate, calcium chloride, magnesium oxide, magnesium hydroxide, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium acetate, sodium tartrate, antioxidants such as butylated hydroxytoluene, butylated hydroxyanisole , citric acid or any other stabilizer.
  • the pharmaceutical composition of the present invention may contain one or more lubricants.
  • Suitable lubricants can be stearic acid, magnesium stearate, calcium stearate, sodium or magnesium laurylsulphate , hydrogenated vegetable oils and fats, hydrogenated castor oil, sodium stearyl fumarate, talc, macrogols, palmitic acid, and combinations thereof.
  • a preferred lubricant is magnesium stearate .
  • One or more glidants can also be added to the composition according to the invention. They can be selected from the group comprising of talc, silicon dioxide of different grades (such as colloidal or precipitated silica) etc.
  • excipents may have multiple functions, i.e. one excipient may function as diluent and additionally binder, binder and disintegrant etc.
  • cores/tablets can be coated with one or more conventional materials used for film coating which can be used to modify the appearance of the solid composition such as smoothness of the surface, taste masking, colour or to change the physical properties of the cores such as ability to absorb moisture or interact with oxygen.
  • the polymers used in film coating can be either cellulose derivatives, such as the cellulose ethers (e.g. hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose and methylcellulose ) , or acrylic polymers and copolymers.
  • such functional film coating in the present invention preferably has decreased permeability for gasses such as moisture and/or oxygen.
  • Functional polymers such as polyvinyl alcohol, calcium carboxymethyl cellulose, graft copolymer of polyethylene glycol and polyvinyl alcohol obtainable as Kollicoat IR or Kollicoat Protect from company BASF, aminoalkyl methacrylate copolymer sold as Eudragit E, Eudragit EPO can be selected for obtaining such functional coating.
  • Other excipients selected from pigment and colorant, plasticizers, glidants and/or antitacking agents can optionally be used in such functional coating .
  • plasticizers are polyols (glycerol, propylene glycol, polyethylene glycols), organic esters (phthalate esters, dibutyl sebacetate, citrate esters, triacetin) and oils/glycerides (castor oil, acetylated monoglycerides, fractionated coconut oil) .
  • Colourants/opacifiers can be added. They are classified into several groups: organic dyes and their lakes, inorganic colours, natural colours.
  • Layering or film coating dispersion can be prepared by using one or more different solvents (water, alcohols, ketones, esters, chlorinated hydrocarbons), preferably water.
  • solvents water, alcohols, ketones, esters, chlorinated hydrocarbons
  • Film coating dispersions can also be used as ready-to-make preparations which are available on the market.
  • the pharmaceutical composition can be prepared as any pharmaceutical solid dosage form, such as powders, granules, pellets, tablets, coated tablets, orodispersible tablets, chewable tablets, mini tablets, multi layered tablets, capsules .
  • the pharmaceutical formulations may be processed by direct compression, dry granulation or wet granulation, extrusion followed by spheronization, etc.
  • Equipment suitable for processing the pharmaceutical formulations can include blenders, granulators (high sheer, fluid bed) , roller compacters, drying machines, tableting machines, coating pans, etc.
  • the pharmaceutical composition of ivabradine hydrochloride might be processed and packed under a modified atmosphere.
  • the atmosphere with the modified oxygen content or reduced oxygen partial pressure may be obtained by the use of a reduced pressure atmosphere, e.g. by creating a partial vacuum by means of a suitable pump or by partial freezing or liquefying the atmosphere, or by the use of an inert gas, such as nitrogen or argon with the oxygen content of less than 8 vol.-%, preferably less than 4 vol.-%, most preferably less than 2 vol.-%, each based on the total gas volume of the respective inert gas, or by the use of oxygen absorbents, even though the high efficacy of such absorbents leading to very low oxygen levels is normally not necessary.
  • the composition is present in a packaging, with a blister packaging or a container made of polymeric material such as high density polyethylene or glass being preferred.
  • the packaging can be provided with means for trapping and disposal of free oxygen.
  • the composition might be enclosed in a substantially gas exchange nonpermeable material as packaging which has an atmosphere with the required reduced oxygen content.
  • the substantially gas exchange non-permeable packaging is preferably selected from the group consisting of an Al/Al blister package, an Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or a container.
  • Low moisture permeable primary packaging materials such as polychloro-3- fluoroethylene homopolymer/PVC laminate can be used with the thickness in the range 270 ⁇ to 360 ⁇ .
  • the solid composition in form of tablets can be packed into containers with a desiccant and/or oxygen absorber mounted into the container closure system and/or into the container walls or added as a capsule into the container filled with solid composition.
  • compositions comprising amorphous ivabradine hydrochloride and a stabilizer selected from maltodextrin, cyclodextrin, hydroxypropylcellulose, carrageenan and/or meglumine. More preferred are pharmaceutical compositions comprising amorphous ivabradine and a stabilizer selected from maltodextrin and/or cyclodextrin. Most preferred are pharmaceutical compositions comprising a coprecipitate of amorphous ivabradine hydrochloride and maltodextrin.
  • the size distribution of ivabradine hydrochloride particles was determined by laser diffraction using a Malvern Mastersizer 2000 laser diffraction instrument.
  • the samples for analysis were prepared by dispersing a weighed amount of ivabradine hydrochloride particles in isopar.
  • ivabradine hydrochloride form Z is dried in vacuo at 22 °C for 2 hours. 5.0 g of crystalline ivabradine hydrochloride is obtained. (KF 1.9 %, LOD 1.8 %)
  • ivabradine hydrochloride 10 g is dissolved in 200 g of purified water and sprayed into spray dryer to obtain amorphous form of ivabradine hydrochloride.
  • ivabradine hydrochloride 10 g is dissolved in 200 g of absolute ethanol and sprayed into spray dryer to obtain amorphous form of ivabradine hydrochloride.
  • the coprecipitate is prepared by spray drying of aqueous solution of ivabradine hydrochloride and other excipients.
  • Ivabradine hydrochloride and stabilizer are dispersed in a suitable solvent, preferably water, ethanol or their mixture thereof, and sprayed into spray dryer to obtain amorphous ivabradine coprecipitate.
  • Amorphous ivabradine hydrochloride coprecipitate and all other components are mixed in an appropriate mixer and pressed into 150 mg round tablets. Optionally, the tablets are film coated.
  • Example 18 Preparation of tablets with amorphous ivabradine hydrochloride
  • Ivabradine hydrochloride is dissolved in a pre-prepared aqueous solution of povidone to form granulating liquid.
  • the granulating liquid is sprayed onto a mixture of maize starch, a part of microcrystalline cellulose and a part of colloidal silicon dioxide, anhydrous in a fluid-bed granulator or high shear mixer.
  • the obtained granulate is dried and sieved.
  • a granulate is mixed with other excipients and pressed into tablets.
  • the tablets are film coated with aqueous dispersion .
  • Example 19 Preparation of tablets with amorphous ivabradine hydrochloride
  • ivabradine Ivabradine hydrochloride and matodextrin are dissolved in purified water while stirring and heating to 40°C.
  • the obtained granulating liquid is sprayed onto a mixture of maize starch, a part of microcrystalline cellulose and a part of colloidal silicon dioxide, anhydrous in a fluid-bed granulator or high shear mixer.
  • the obtained granulate is dried, sieved and mixed with the other part of microcrystalline cellulose and colloidal silicon dioxide, anhydrous.
  • At the end magnesium stearate is admixed.
  • the tabletting mixture is pressed into tablets.
  • the tablets are film coated with aqueous dispersion of Opadry in a suitable coating pan.
  • Example 20 Preparation of tablets of amorphous ivabradine hydrochloride
  • Meglumine and butylated hydroxytoluene are dissolved in a mixture of ethanol and purified water. A weight ratio of ethanol : purified water 5:2- was used. Ivabradine hydrochloride is added and dissolved. The obtained granulating liquid is sprayed onto a mixture of Avicel PH 101 and a part of colloidal silicon dioxide, anhydrous in a suitable granulator. Ethanol and purified water evaporate during the granulating process. The dry granulate is sieved. A granulate is mixed with other excipients and pressed into tablets. Optionally, the tablets are film coated in a suitable coating pan.
  • Example 21 Preparation of tablets with amorphous ivabradine hydrochloride
  • Ivabradine hydrochloride and ⁇ - ⁇ -CD are dissolved in purified water and sprayed onto Avicel PH 101 in a fluid-bed granulator or a high sheer mixer. Wet granulate is dried and sieved. Excess ⁇ - ⁇ -CD (weight ratio 2:9) is employed to ensure the complete complexation of ivabradine in solid form. In addition, the obtained dry granulate is mixed with other excipients and pressed into tablets.
  • Example 22 Preparation of tablets with amorphous ivabradine hydrochloride
  • Maltodextrin (Lycatab DSH) is dissolved in purified water. Ivabradine hydrochloride is added and dissolved while heating up to 40°C. The obtained solution is sprayed onto a mixture of microcrystalline cellulose (Avicel PH101), maize starch and a part of colloidal silicon dioxide, anhydrous in a high shear mixer. The wet granulate is dried and sieved. Microcrystalline cellulose (Avicel PH200) and the other part of colloidal silicon dioxide, anhydrous are added and mixed in a suitable mixer. At the end magnesium stearate is admixed and the obtained tabletting mixture is pressed into tablets.
  • the tablet cores are film coated with aqueous dispersion of Opadry Orange 03H32599 in a suitable coating pan.
  • Opadry Orange 03H32599 is a ready-to-use dry blend containing polymer, plasticizer and pigment. During film coating process the weight gain of the tablet cores of 5 % is achieved.
  • Example 23 Packaging of the tablets prepared as described in Example 22
  • the tablets of ivabradine hydrochloride from Example 22 are packed in Al/Al blisters under a nitrogen atmosphere with the oxygen content from 1 to 2 vol. %.
  • Table 1 Comparative stability data of amorphous ivabradine hydrochloride according to example 5 and example 23 held at 50°C and 75% relative humidity for 1 month:
  • Hypromellose (Pharmacoat 603) and Maltodextrin (Glucidex 19) are dissolved in heated purified water (up to 40°C) .
  • Ivabradine hydrochloride and ethanol are added and mixed until complete active substance is dissolved into clear solution.
  • a weight ratio purified water : ethanol of 3.5 : 1 is used.
  • the obtained granulating liquid is sprayed onto a mixture of microcrystalline cellulose (Avicel PH101) and maize starch in a fluid-bed granulator or high shear mixer.
  • the wet granulate is dried up to the product temperature 25-60°C.
  • the dry granulate is sieved.
  • Microcrystalline cellulose (Avicel PH200) and colloidal silicon dioxide, anhydrous are added and mixed in a suitable mixer. At the end magnesium stearate is admixed and the obtained tabletting mixture is pressed into tablets.
  • the tablet cores are film coated with aqueous dispersion of Opadry Orange 03H32599 in a suitable coating pan.
  • Opadry Orange 03H32599 is a ready-to-use dry blend containing polymer, plasticizer and pigment. During film coating process the weight gain of the tablet cores of 3-5 % is achieved.
  • Example 25 Preparation of tablets with amorphous ivabradine hydrochloride
  • Hypromellose and Maltodextrin are dissolved in heated purified water (up to 40 °C). Ivabradine hydrochloride is added and dissolved. Ethanol is added into a solution. The obtained granulating liquid is sprayed onto a mixture of microcrystalline cellulose (Avicel PH101) and maize starch in a fluid-bed granulator. The dry granulate is sieved. Microcrystalline cellulose (Avicel PH200) and colloidal silicon dioxide, anhydrous are added and mixed in a suitable mixer. At the end magnesium stearate is admixed and the obtained tabletting mixture is pressed into tablets. The tablet cores are film coated with aqueous dispersion of Opadry Orange 03H32599. During film coating process the weight gain of the tablet cores of 3-5% is achieved.
  • Example 26 Preparation of tablets with amorphous ivabradine hydrochloride
  • the formulation is prepared by wet granulation.
  • a mixture of microcrystalline cellulose (Vivapur 101) and maize starch is granulated with an ethanol-water solution of ivabradine hydrochloride, hypromellose (Pharmacoat 603) and maltodextrin (Glucidex 19) .
  • the granulation liquid was prepared in such a way that hypromellose and maltodextrin are dissolved in heated purified water (up to 40°C). Ivabradine hydrochloride and ethanol are added and mixed until a clear solution is obtained.
  • a weight ratio purified water : ethanol of 4 : 1 or 5 : 2 is used.
  • the wet granulate is dried up to the product temperature 25-60 °C.
  • Example 27 Preparation of tablets with amorphous ivabradine hydrochloride
  • the formulation is, prepared by wet granulation in a high shear mixer.
  • a mixture of microcrystalline cellulose (Vivapur 101) and maize starch is granulated with an ethanol-water solution of ivabradine hydrochloride, hypromellose (Pharmacoat 603) and maltodextrin (Glucidex 19) .
  • Prepared granulate is mixed with microcrystalline cellulose (Vivapur 12) and colloidal silicon dioxide, anhydrous.
  • Magnesium stearate is admixed and the obtained tabletting mixture is pressed into tablets.
  • the tablet cores are film coated with aqueous dispersion of Opadry Orange 03H32599. During film coating process the weight gain of the tablet cores of 5% is achieved.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne de nouvelles formes cristallines de chlorhydrate d'ivabradine et des compositions pharmaceutiques préparées à partir de celles-ci.
EP11702672A 2010-02-12 2011-02-11 Nouvelles formes de chlorhydrate d'ivabradine Withdrawn EP2534135A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15151073.2A EP2902384B1 (fr) 2010-02-12 2011-02-11 Forme de chlorhydrate d'ivabradine
PL15151073T PL2902384T3 (pl) 2010-02-12 2011-02-11 Postać chlorowodorku iwabradyny

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI201000057 2010-02-12
PCT/EP2011/052068 WO2011098582A2 (fr) 2010-02-12 2011-02-11 Nouvelles formes de chlorhydrate d'ivabradine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15151073.2A Division EP2902384B1 (fr) 2010-02-12 2011-02-11 Forme de chlorhydrate d'ivabradine

Publications (1)

Publication Number Publication Date
EP2534135A2 true EP2534135A2 (fr) 2012-12-19

Family

ID=43770633

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11702672A Withdrawn EP2534135A2 (fr) 2010-02-12 2011-02-11 Nouvelles formes de chlorhydrate d'ivabradine
EP15151073.2A Active EP2902384B1 (fr) 2010-02-12 2011-02-11 Forme de chlorhydrate d'ivabradine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15151073.2A Active EP2902384B1 (fr) 2010-02-12 2011-02-11 Forme de chlorhydrate d'ivabradine

Country Status (6)

Country Link
EP (2) EP2534135A2 (fr)
EA (1) EA201290772A1 (fr)
HU (1) HUE035588T2 (fr)
PL (1) PL2902384T3 (fr)
SI (2) SI23290A (fr)
WO (1) WO2011098582A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800444C (fr) * 2010-06-14 2018-03-20 Ratiopharm Gmbh Composition pharmaceutique contenant de l'ivabradine
WO2012025940A1 (fr) * 2010-08-25 2012-03-01 Cadila Healthcare Limited Forme polymorphe du chlorhydrate d'ivabradine et son procédé de préparation
EP3318247A1 (fr) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Composition pharmaceutique au goût masqué
EP2589594A1 (fr) * 2011-11-04 2013-05-08 Urquima S.A. Forme IV d'hydrochlorure d'ivabridine
EP3156399A1 (fr) * 2011-11-14 2017-04-19 Cadila Healthcare Limited Formes polymorphes de chlorhydrate d'ivabradine
WO2013150544A2 (fr) * 2012-04-02 2013-10-10 Hetero Research Foundation Dispersion solide de chlorhydrate d'ivabradine
WO2014024210A2 (fr) * 2012-08-10 2014-02-13 Hetero Research Foundation Nouveaux polymorphes du doxercalciférol
EP2953612A1 (fr) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit d'éléments
HRP20200300T4 (hr) 2013-03-19 2023-09-15 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida i metoda za njegovu pripremu
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
WO2015001569A1 (fr) * 2013-07-02 2015-01-08 Genepharm India Private Limited Composition pharmaceutique solide d'ivabradine à administrer par voie orale
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es) 2013-12-12 2019-03-20 Synthon Bv Composicion farmaceutica que comprende ivabradina amorfa.
EP3082772A1 (fr) * 2013-12-20 2016-10-26 Synhton B.V. Composition pharmaceutique comprenant de l'ivabradine amorphe
EP2774606B1 (fr) * 2014-02-14 2019-01-30 Synthon B.V. Composition pharmaceutique comprenant le polymorphe IV d'hydrochlorure d'ivabradine
EP3122362A1 (fr) * 2014-03-27 2017-02-01 Laboratorio Chimico Internazionale S.p.A. Adsorbats d'ivabradine
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
TR201703066A2 (tr) * 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (fr) * 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques orales solides d'ivabradine
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
WO2023094048A1 (fr) * 2021-11-24 2023-06-01 Nutrition & Biosciences Usa 1, Llc Procédé de production de cellulose microcristalline à teneur réduite en sels de nitrite

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868775B1 (fr) 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868777B1 (fr) 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868776B1 (fr) 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2870537A1 (fr) 2004-05-19 2005-11-25 Servier Lab Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
ATE544754T1 (de) 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
WO2008125006A1 (fr) 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
WO2008146308A2 (fr) * 2007-05-30 2008-12-04 Ind-Swift Laboratories Limited Procédé de préparation de chlorhydrate d'ivabradine et polymorphe correspondant
CN101434552B (zh) 2007-11-16 2012-05-23 江苏恒瑞医药股份有限公司 4,5-二甲氧基-1-(甲基氨基甲基)-苯并环丁烷的拆分
CN101544605A (zh) 2008-03-24 2009-09-30 北京深蓝海生物医药科技有限公司 伊伐布雷定及其药学上可接受的加成盐的制备方法
CN101343249A (zh) 2008-06-10 2009-01-14 上海医药工业研究院 3－(3－氯丙基)－7,8－二甲氧基－1,3－二氢－2h－3－苯并氮杂－2－酮的制备方法
FR2932800B1 (fr) 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011098582A2 *

Also Published As

Publication number Publication date
PL2902384T3 (pl) 2018-04-30
WO2011098582A3 (fr) 2012-03-01
EP2902384B1 (fr) 2017-11-08
EA201290772A1 (ru) 2013-02-28
HUE035588T2 (en) 2018-05-28
SI23290A (sl) 2011-08-31
SI2902384T1 (en) 2018-03-30
WO2011098582A2 (fr) 2011-08-18
EP2902384A1 (fr) 2015-08-05

Similar Documents

Publication Publication Date Title
EP2902384B1 (fr) Forme de chlorhydrate d'ivabradine
EP2398468B1 (fr) Compositions pharmaceutiques comprenant du prasugrel ou ses sels d'addition d'acide pharmaceutiquement acceptables, et leurs procédés de préparation
EP2459531B1 (fr) Granulés comprenant de la vildagliptine et son procédé de préparation
JP2018184410A (ja) 非晶質ダパグリフロジンを含有する製剤
EP2120882A2 (fr) Composition pharmaceutique comprenant un inhibiteur d'absorption du cholestérol
EP2691083B1 (fr) Composition pharmaceutique de sitagliptine
CA2940984A1 (fr) Compositions pharmaceutiques solides d'antagonistes du recepteur des androgenes
EP2303866B1 (fr) Nouvelles formes cristallines du rabéprazole sodique
EP2276742B1 (fr) Bromhydrate d'ivabradine
WO2011039369A2 (fr) Formes amorphes d'un dérivé de 2-amino-4-(4-fluorobenzylamino)phénylcarbamate
JP6215940B2 (ja) ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［（４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたはその医薬的に許容され得る塩を含む安定な医薬組成物
WO2016097314A1 (fr) Formes amorphes et cristallines d'idélalisib et procédé pour les produire
EP2119695A1 (fr) Préparation de sels de O-desméthylvenlafaxine
EP3048104A1 (fr) Idelalisib amorphe et des forms cristalline et leur procédé de fabrication
WO2021130226A1 (fr) Composition pour la préparation de granulés d'arginine de périndopril, son procédé de préparation et composition pharmaceutique comprenant les granulés
EP2119696A1 (fr) Préparation de sels de O-desméthylvenlafaxine
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
WO2016198154A1 (fr) Composition pharmaceutique comprenant du chlorhydrate d'ivabradine et procédé pour la préparer
WO2024096838A1 (fr) Composition pharmaceutique comprenant une dispersion solide d'empagliflozine
EP2376476B1 (fr) Procédé de synthèse d'ésoméprazole

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120830

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20131031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150312